ARCHIVES

In Brief: Oldham To Head Biological Response Modifiers Program; Walter, Namovicz Named Acting Heads

This article is from The Cancer Letter archive.

Vol. 06 No. 32 | August 8, 1980

Download PDF Visit The Full Archive

Related Articles

Mendelsohn To Step Down As MD Anderson President

December 10, 2010

Pharmacia Corp. Forms $1 Million Fund To Support Anthracycline Research.

June 2, 2000

Platinum-Free Break Enhances Therapy After First Relapse In Ovarian Cancer

March 28, 2003

GSK’s Pazopanib Benefits Similar to Sunitinib; Sponsor Points to More Favorable Safety Profile

August 30, 2013

No Justification Provided: DePinho’s Nixing of Tenure Renewals May Bring Censure to MD Anderson

April 25, 2014

Hairy Cell Leukemia Patients Have CRs In Phase I Trial

September 28, 2001